查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1656902

經皮藥物輸送設備:市場洞察·競爭情形·市場預測 (～2032年)

Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

透皮給藥裝置市場規模預計將從 2024 年的 71,566,270 百萬美元增長到 2032 年的 121,798,760 百萬美元，預測期內的複合年增長率為 6.91%。

慢性病盛行率的不斷上升和第三代透皮給藥裝置的日益普及，極大地促進了此類裝置的全球市場的發展。技術進步提高了設備的效率，改善了藥物吸收並方便了患者。此外，它在荷爾蒙失調、心血管疾病、疼痛管理和其他領域的多種應用，提供非侵入性、可控和患者友好的藥物傳輸選擇，進一步推動了需求。這些因素共同推動了 2025-2032 年預測期內透皮給藥裝置的使用和發展在全球範圍內的擴大。

根據類型，含藥貼片部分預計將在 2024 年佔據市場主導地位，佔有率為 55.44%。預計在預測期內，這些黏性貼片所提供的各種好處和應用將推動其需求。含藥黏性透皮貼片是一種藥物輸送系統，旨在透過皮膚將藥物輸送到血液中。這些貼片旨在隨著時間推移釋放藥物，提供可控且一致的治療劑量。黏合層有助於將貼片黏附在皮膚上，並控制藥物釋放的速度。一旦將貼片貼到皮膚上，藥物就會逐漸透過皮膚擴散到血液中，隨著時間的推移，藥物會穩定且可控地釋放。

按地區劃分，預計北美將在 2024 年佔據最大佔有率，為 45.39%，並在預測期內以 5.91% 的複合年增長率增長。這被認為是由於該地區慢性疼痛、中樞神經系統疾病和心血管疾病等目標疾病的盛行率不斷增加、新產品的推出以及對研發活動的重視程度而不斷提高。

本報告提供全球經皮藥物輸送設備的市場調查，彙整市場概要，市場影響因素及市場機會分析，法律制度，市場規模的轉變·預測，各種區分·地區/各主要國家的詳細分析，競爭情形，主要企業簡介等資訊。

目錄

第1章 經皮藥物輸送設備市場報告:簡介

  • 調查範圍
  • 市場區隔
  • 市場前提條件

第2章 經皮藥物輸送設備市場:摘要整理

  • 市場概要

第3章 競爭情形

第4章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 經皮藥物輸送設備市場:主要要素分析

  • 推動市場要素
    • 慢性病發生率上升
    • 第三代透皮給藥裝置的採用日益廣泛
    • 科技進步日新月異
    • 全球範圍內設備的使用日益廣泛：從荷爾蒙失調到心血管疾病再到疼痛管理
  • 市場限制與課題
    • 與透皮給藥裝置相關的限制（例如應用部位的刺激和腫脹）
    • 增加產品召回
  • 市場機會
    • 提高對透皮給藥裝置的認識
    • 越來越多的患者採用無痛透皮給藥裝置

第6章 經皮藥物輸送設備市場:波特的五力分析

第7章 經皮藥物輸送設備市場評估

  • 各類型
    • 含藥貼劑
    • 矩陣補丁
    • 儲庫膜貼片
    • 微針貼片
  • 各用途
    • 疼痛管理
    • 中樞神經系統疾病
    • 荷爾蒙
    • 心血管疾病
    • 其他
  • 各終端用戶
    • 醫院
    • 門診病人手術中心
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 經皮藥物輸送設備市場:企業·產品簡介

  • Novartis
  • Viatris Inc.
  • UCB SA
  • Hisamitsu Pharmaceutical
  • Boehringer Ingelheim
  • Johnson & Johnson Services Inc.
  • Purdue Pharma
  • Bayer AG
  • Haleon Group of Companies
  • Ingenus Pharmaceuticals
  • Luye Pharma Group
  • Cumberland Pharmaceuticals Inc.
  • Sanofi
  • Sparsha Pharma International Pvt Ltd.
  • Cipla

第9章 KOL的見解

第10章 計劃的方法

第11章 關於DelveInsight

第12章 免責聲明·聯絡方式

Product Code: DIMDCL0048

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.

The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

Transdermal Drug Delivery Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.

Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.

Additionally, the increase in strategic activities among the key market players is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.

Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.

However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.

Transdermal Drug Delivery Devices Market Segment Analysis:

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the market with a market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.

Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.

Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.

North America is expected to dominate the overall transdermal drug delivery devices market:

Among all regions, North America is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson's Foundation (2022), nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.

Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA(R) on-body injector (OBI) through its Sorrel(TM) platform. UDENYCA(R) (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.

Thus, the above-mentioned factors are expected to escalate the market of transdermal drug delivery devices in the region.

Transdermal Drug Delivery Devices Market Key Players:

Some of the key market players operating in the transdermal drug delivery devices market include Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:

  • In July 2024, Kindeva Drug Delivery's Woodbury, MN facility was FDA-inspected and classified. The facility now supports clients with integrated and stand-alone analytical services for pharmaceutical, biopharmaceutical, and medical device sectors.
  • In March 2024, PassPort Technologies, Inc., a San Diego-based clinical-stage company, reported positive interim results from its Phase 1 trial of Zolmitriptan PassPort(R), using a proprietary transdermal microporation system for acute migraine treatment. Zolmitriptan, an FDA-approved migraine medication, is tested for efficacy via this new delivery system.

Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study

  • Market size analysis for current transdermal drug delivery devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the transdermal drug delivery devices market.
  • Various opportunities available for the other competitors in the transdermal drug delivery devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current transdermal drug delivery devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for transdermal drug delivery devices market growth in the coming future?

Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study

  • Transdermal drug delivery devices product providers
  • Research organizations and consulting companies
  • Transdermal Drug Delivery Devices -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in transdermal drug delivery devices
  • Various end-users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.

Frequently Asked Questions for the Transdermal Drug Delivery Devices Market:

1. What are transdermal drug delivery devices?

  • Transdermal drug delivery (TDD) is a method that delivers drugs through the skin for controlled, sustained release over time. It improves patient compliance and avoids first-pass metabolism in the liver, providing an appealing alternative to oral and hypodermic drug administration.

2. What is the market for transdermal drug delivery devices?

  • The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032.

3. What are the drivers for the global transdermal drug delivery devices market?

  • The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global transdermal drug delivery devices market?

  • Some of the key market players operating in the transdermal drug delivery devices are Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

5. Which region has the highest share in the global transdermal drug delivery devices market?

  • North America region is anticipated to dominate the overall transdermal drug delivery devices market due to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

Table of Contents

1. Transdermal Drug Delivery Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Transdermal Drug Delivery Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Transdermal Drug Delivery Devices Market Key Factors Analysis

  • 5.1. Transdermal Drug Delivery Devices Market Drivers
    • 5.1.1. The increasing prevalence of chronic conditions
    • 5.1.2. Increase in adoption of third-generation transdermal drug delivery devices
    • 5.1.3. Increase in the technological advancements
    • 5.1.4. Increase use of these devices for hormonal disorders to cardiovascular conditions and pain management across the globe
  • 5.2. Transdermal Drug Delivery Devices Market Restraints and Challenges
    • 5.2.1. Limitation associated with transdermal drug delivery devices such as irritation at site of application and edema
    • 5.2.2. Increase product recalls
  • 5.3. Transdermal Drug Delivery Devices Market Opportunities
    • 5.3.1. Increasing awareness towards transdermal drug delivery devices
    • 5.3.2. Increased patient adoption for pain-less transdermal drug delivery devices

6. Transdermal Drug Delivery Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Transdermal Drug Delivery Devices Market Assessment

  • 7.1. By Type
    • 7.1.1. Drug-in-adhesive Patches
    • 7.1.2. Matrix Patches
    • 7.1.3. Reservoir Membrane Patches
    • 7.1.4. Microneedle Patches
  • 7.2. By Application
    • 7.2.1. Pain Management
    • 7.2.2. Central Nervous System Disorders
    • 7.2.3. Hormonal Applications
    • 7.2.4. Cardiovascular Disorders
    • 7.2.5. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.1.2. Canada Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.1.3. Mexico Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.2. Germany Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.3. United Kingdom Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.4. Italy Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.5. Spain Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.2.6. Rest of Europe Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.2. Japan Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.3. India Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.4. Australia Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.5. South Korea Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.4.2. Africa Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
      • 7.4.4.3. South America Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)

8. Transdermal Drug Delivery Devices Market Company and Product Profiles

  • 8.1. Novartis
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Viatris Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. UCB SA
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Hisamitsu Pharmaceutical
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Boehringer Ingelheim
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Johnson & Johnson Services Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Purdue Pharma
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Bayer AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Haleon Group of Companies
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Ingenus Pharmaceuticals
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Luye Pharma Group
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Cumberland Pharmaceuticals Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Sanofi
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Sparsha Pharma International Pvt Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Cipla
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
  • Table 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
  • Table 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
  • Table 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
  • Table 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
  • Table 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
  • Table 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
  • Table 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
  • Table 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
  • Table 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
  • Table 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
  • Table 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
  • Table 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
  • Table 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
  • Table 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
  • Table 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
  • Table 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
  • Table 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
  • Table 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
  • Table 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
  • Table 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
  • Table 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
  • Table 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
  • Table 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
  • Table 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
  • Table 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
  • Figure 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
  • Figure 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
  • Figure 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
  • Figure 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
  • Figure 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
  • Figure 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
  • Figure 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
  • Figure 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
  • Figure 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
  • Figure 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
  • Figure 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
  • Figure 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
  • Figure 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
  • Figure 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
  • Figure 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
  • Figure 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
  • Figure 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
  • Figure 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
  • Figure 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
  • Figure 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
  • Figure 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
  • Figure 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
  • Figure 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
  • Figure 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
  • Figure 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Market Opportunities
  • Figure 32: PORTER'S Five Force Analysis